HER2与CD163在胃癌中的表达及意义  

Expression and clinical significance of HER2 and CD163 in human gastric cancer

作　　者：楼亚玲[1,2] 丁玲[1] 徐炜[3] 刘进[3] 杨水新[2] 叶勇[2] 

机构地区：[1]浙江大学药学院,浙江杭州310058 [2]湖州市中心医院药学部,浙江湖州313003 [3]湖州市中心医院病理科,浙江湖州313003

出　　处：《实用肿瘤杂志》2016年第2期131-134,共4页Journal of Practical Oncology

基　　金：湖州市科技局自然科学基金项目(2014YZB)

摘　　要：目的研究人表皮生长因子受体-2(human epidermal growth factor receptor-2,HER2)与M2型巨噬细胞表面标志物分化抗原簇163(cluster of differentiation 163,CD163)在胃癌组织中的表达及意义。方法应用免疫组织化学方法检测45例胃癌和癌旁组织标本中HER2、CD163和CD68蛋白的表达,并将检测结果与患者临床病理资料相结合进行综合分析。结果胃癌组织中的CD163^+和CD68^+细胞数目高于癌旁组织(均P<0.05),HER2阳性表达在肿瘤p TNM分期、有无淋巴结转移等方面差异有统计学意义(均P<0.05)。CD163^+M2巨噬细胞数在肿瘤p TNM分期方面差异有统计学意义(P<0.05)。HER2蛋白表达与CD163^+M2性巨噬细胞数目存在相关性(r=0.61,P<0.05)。结论 HER2表达强度与M2型巨噬细胞数目存在相关性,二者是判断胃癌诊断、治疗及预后的重要参考指标。Objective To investigate the expression and significance of human epidermal growth factor receptor-2（HER2） and M2-type macrophage surface marker cluster of differentiation 163（ CD163） in human gastric cancer,and their relationship with clinicopathological features of the cancer. Methods The expression of HER2,CD163 and CD68 were examined by immunohistochemistry in 45 specimens of gastric cancer tissues and cancer-adjacent normal tissues. The association of their expression with clinicopathologic features was analyzed. Results The expressions of CD163 and CD68 in gastric cancer tissue were significantly higher than those in adjacent normal gastric tissues（ P〈0. 05）. The expression of HER2 protein in gastric cancer tissues differred in cases with different tumor p TNM staging and status of lymph node metastasis（ P〈0. 05）. Meanwhile,the number of CD163-＋M2 macrophages differred in cases with different p TNM staging（ P〈0. 05）. Moreover,HER2 expression was positively correlated with the number of CD163-＋M2 macrophages in gastric cancer tissue（ r = 0. 61,P〈0. 05）. Conclusion HER2 expression is correlated with the number of CD163-＋M2 macrophages,and both may be used for diagnoses,treatment and prognosis of gastric cancer.

关 键 词：胃肿瘤/病理学 受体 表皮生长因子 巨噬细胞 抗原 CD 免疫组织化学 预后 

分 类 号：R735.2[医药卫生—肿瘤] R730.23[医药卫生—临床医学]